StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.96+0.01 (+0.34%)

Close on Nov 20, 2026Market cap $242.86MP/E –Yield –

Lexeo Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lexeo Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$88.70M. For fiscal 2025 it was -$98.96M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$98.96M–
FY2024Dec 31, 2024-$81.63M–
FY2023Dec 31, 2023-$59.61M–
FY2022Dec 31, 2022-$55.23M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.60M–
Q1 FY2026Mar 31, 2026-$21.18M–
Q4 FY2025Dec 31, 2025-$20.08M–
Q3 FY2025Sep 30, 2025-$29.84M–
Q4 FY2024Dec 31, 2024-$28.33M–
Q3 FY2024Sep 30, 2024-$17.89M–
Q2 FY2024Jun 30, 2024-$20.37M–
Q1 FY2024Mar 31, 2024-$15.05M–
Q4 FY2023Dec 31, 2023-$14.05M–
Q3 FY2023Sep 30, 2023-$13.95M–
Q4 FY2022Dec 31, 2022-$16.65M–

More Lexeo Therapeutics figures

See a number that looks wrong?